2. Search Result
Search Result
Results for "

EGFR/HER2-IN-2

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

3

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164718
    Sevabertinib

    BAY 2927088

    		 EGFR Cancer
    Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor (IC 50 <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer .
    Sevabertinib
  • HY-N1073
    Wighteone
    1 Publications Verification

    6-IsopentenylgenisteIN; ErythrININ B

    		 Apoptosis EGFR HSP ERK Akt Infection Cancer
    Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR L858R/T790M mutation, and fungal infections .
    Wighteone
  • HY-E70715
    ERBB2 775YVMA776 Recombinant Human Active Protein Kinase

    		EGFR Cancer
    The erbB family comprises 4 structurally related receptors: ErbB1 (EGFR), ErbB2 (HER2-neu), ErbB3 and ErbB4. On ligand stimulation, the receptor forms either homodimers or heterodimers, which activate their cytoplasmic domain. ERBB2 775YVMA776 Recombinant Human Active Protein Kinase is a recombinant ERBB2 775YVMA776 protein that can be used to study ERBB2 775YVMA776-related functions .
    ERBB2 775YVMA776 Recombinant Human Active Protein Kinase
  • HY-150023
    BI-1622

    		EGFR Itk PI4K Btk CDK Raf JAK Cancer
    BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile .
    BI-1622
  • HY-115951
    EGFR/HER2-IN-2

    		EGFR Cancer
    EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of EGFR and HER2 with IC50 values of 5.02 µM and 0.83 µM against EGFR and HER2, respectively .
    EGFR/HER2-IN-2
  • HY-153856
    TAS2940

    		EGFR Cancer
    TAS2940 is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .
    TAS2940
  • HY-149636
    Multi-target kinase inhibitor 2

    		EGFR CDK VEGFR Apoptosis Cancer
    Multi-target kinase inhibitor 2 is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC50 values of 79 nM, 40 nM,136 nM, and 204 nM, respectively. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC50 of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells .
    Multi-target kinase inhibitor 2
  • HY-P991234
    COVA208

    		EGFR p38 MAPK PI3K Akt Cancer
    COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .
    COVA208
  • HY-174841
    EGFR/HER2-IN-19

    		EGFR Cancer
    EGFR/HER2-IN-19 (Compound L1) is a dual inhibitor against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-19 is promising for research of cancers driven by EGFR/HER2 .
    EGFR/HER2-IN-19
  • HY-172623
    EGFR/HER2-IN-17

    		EGFR Caspase Apoptosis Bcl-2 Family Cancer
    EGFR/HER2-IN-17 (Compound 7h) is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-17 inhibits cancer cell proliferation. EGFR/HER2-IN-17 interacts with the binding pockets of EGFR and HER2, activating caspase-3 and caspase-8, and decreases the expression of Bcl-2, thereby inducing apoptosis. EGFR/HER2-IN-17 is promising for research of cancers .
    EGFR/HER2-IN-17
  • HY-143734
    HER2-IN-6

    		EGFR Cancer
    HER2-IN-6 is a potent inhibitor of HER2. HER2-IN-6 has the potential for the research of wild and/or mutant EGFR and/or HER2 kinase mediated tumor (extracted from patent WO2021164697A1, compound 11) .
    HER2-IN-6
  • HY-153856A
    TAS2940 fumarate

    		EGFR Cancer
    TAS2940 fumarate is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 fumarate against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC50 values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 fumarate can be used for the study of tumors with HER2 and EGFR aberrations .
    TAS2940 fumarate
  • HY-169216
    Multi-target kinase inhibitor 3

    		EGFR VEGFR CDK Cancer
    Multi-target kinase inhibitor 3 (compund 6i) is a multi-kinase target inhibitor with anticancer activity. Multi-target kinase inhibitor 3 inhibits EGFR, HER2, VEGFR-2, and CDK2 with IC50s of 0.063 μM, 0.054 μM, 0.119 μM, and 0.448 μM, respectively. Multi-target kinase inhibitor 3 has a good inhibitory effect on breast cancer cells MCF-7, with an IC50 of 6.10 μM .
    Multi-target kinase inhibitor 3
  • HY-P991977
    BSI-001

    5G9

    		 EGFR Apoptosis PARP Akt ERK Cancer
    BSI-001 (5G9) is a HER2-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of HER2-positive breast cancer and HER2-overexpressing gastric cancer .
    BSI-001
  • HY-177895
    IAM1363

    		EGFR Cancer
    IAM1363 is a selective, irreversible and brain-penetrant HER2 inhibitor. IAM1363 shows over 1,000-fold selectivity for HER2 compared to EGFR. IAM1363 can be used for the study of advanced HER2 cancers, such as HER2-driven non-small cell lung cancer (NSCLC) .
    IAM1363
  • HY-P991780
    Anti-Mouse HER2 (domain I) Antibody (H2Mab-304)

    		EGFR Cancer
    Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) reacts with domain I of mouse HER2. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).
    Anti-Mouse HER2 (domain I) Antibody (H2Mab-304)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: